Ensysce Biosciences (NASDAQ:ENSC) is a biotech firm focused on developing innovative solutions in the pharmaceutical field, with a keen emphasis on therapies that aim to prevent prescription drug abuse. It specializes in utilizing its proprietary TAAP™ and MPAR™ technologies to create abuse-deterrent opioids and overdose protection drugs, tackling the growing opioid crisis head-on. The company's projects range from preclinical development to advanced clinical trials, aiming to significantly improve patient safety and adherence. Ensysce's objectives include advancing its pipeline products through regulatory approvals, commercializing its technologies, and establishing partnerships to enhance its market footprint, ultimately striving to provide safer therapeutic options for pain management and addressing the unmet needs in addiction prevention.